THYMOX™ Announces Former Executive Director of Merial, Don Schwartz, appointed Chairman of the Board

SHERBROOKE, Quebec, Dec. 05, 2017 -- THYMOX™, the innovative, botanically-derived brand of animal health products by Laboratoire M2, has announced that Don Schwartz recently joined the Board of Directors and has been appointed Chairman of the Board. Mr. Schwartz brings over 30 years of technical and commercial expertise in Animal Health and related industries.

Don Schwartz

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/a605cd6f-84ac-4842-bee7-f0823fb68890

Mr. Schwartz originally joined Merck & Co., Inc. as Manager of Global Marketing communications. In 1997 Merck entered into a joint venture with French pharmaceutical company Rhône Merieux to form Merial where Mr. Schwartz was promoted to increasing levels of responsibility until his most recent role as an Executive Director of Merial’s US Business Operations. His scope of responsibilities included business development, market research, regulatory affairs, customer care, veterinary technical solutions, public affairs and business analysis.  During the course of his tenure with Merial, Mr. Schwartz was instrumental in the launch of several of the company’s landmark products including IVOMEC, HEARTGARD and FRONTLINE PLUS.  Mr. Schwartz is the author of several books including, Genus Bos, Cattle Breeds of the World, the standard reference on the subject.

“We are very pleased to have such a distinguished member of the Animal Health field join our Board of Directors, and we tremendously value his insights and expertise," commented Thymox CEO, Frank Palantoni. Mr. Schwartz recently retired from Merial, now part of Boeringer Ingelheim, where he contributed significantly to the company’s success throughout his career. Most recently he was Executive Director of Merial, a Sanofi company, were he led the development of the OraVet line of oral care products.

Andrée-Lise Méthot, Founder and Managing Partner of Cycle Capital, THYMOX's largest shareholder, commented, "The recruitment of Don Schwartz as Chairman of the Board will provide strong product, regulatory and strategic leadership to Lab M2 as the company continues to execute its growth plan in the US and internationally. Further, the breadth of Don's experience and expertise will help support and provide guidance as the company continues to expand its R&D program."

About Laboratoire M2
Laboratoire M2, based in Sherbrooke, Canada, has a well-respected reputation for product innovation and expertise in environmentally sustainable, green disinfection and bio-security technology under the trademark THYMOX™. The company markets a range of leading biodegradable, environmentally compliant (UL Ecologo2794), disinfecting and anti-microbial products based on their proprietary technology platform. Animal Health products include THYMOX HOOF® which is used to control the spread of treponemes and other bacteria that cause digital dermatitis (DD). There are an estimated 270 million dairy cows worldwide, producing about $240 billion USD of milk annually, which are susceptible to DD. The expanding availability of THYMOX FOOTBATH offers farmers significantly improved hoof health and enormous productivity savings. Importantly, the use of THYMOX footbaths will remove millions of pounds of toxic chemicals from the farm workplace and the environment.  THYMOX also distributes products and ingredients under private label agreements in institutional, retail, and crop protection markets. For more information about Laboratoire M2 please visit: thymox.com

CONTACT: Marcia Clark
[email protected] / 914-523-9314